gauzy

Gauzy is a global leader in Smart Glass and ADAS technologies, focused on the research, development, manufacturing, and marketing of vision and light control technologies and systems. We believe in innovation that matters. By making materials that do more, we reimagine how we interact with our surroundings and the spaces we spend our time most through light, and the control of it. Through direct fulfillment and a certified distribution channel spanning over 40 countries, Gauzy serves leading brands in automotive, transportation, aeronautics, architecture, consumer goods, medical devices, and beyond. Joining the Gauzy team means being part of an elite group of innovators with a passion for creating groundbreaking products that shape our everyday lives. At Gauzy, we value hard work, unique ideas, collaboration, and cultural diversity. Gauzy has 14 offices globally and over 500 employees. Comprised of four distinct business units– Gauzy Automotive, Gauzy Architecture, Gauzy Vision Systems, and Gauzy Safety Tech – we offer a wide range of career paths to achieve your professional goals. To apply for a position at Gauzy, visit gauzy.com/careers To speak with a sales representative at Gauzy, visit gauzy.com/contact

quantum israel

Compugen

Compugen is a clinical-stage therapeutic discovery and development company utilizing its broadly applicable predictive AI/ML powered computational discovery platform (Unigen™) to identify new drug targets and biological pathways for developing cancer immunotherapies. Compugen has two proprietary product candidates in Phase 1 development: COM701, a potential first-in-class anti-PVRIG antibody and COM902, a potential best-in-class antibody targeting TIGIT for the treatment of solid tumors. Rilvegostomig, a PD-1/TIGIT bispecific antibody where the TIGIT component is derived from Compugen’s clinical stage anti-TIGIT antibody, COM902, is in Phase 3 development by AstraZeneca through a license agreement for the development of bispecific and multispecific antibodies. GS-0321 (previously COM503), a potential first-in-class, high affinity anti-IL-18 binding protein antibody, which is in Phase 1 development is licensed to Gilead. In addition, the Company’s therapeutic pipeline of early-stage immuno-oncology programs consists of research programs aiming to address new mechanisms to activate the immune system against cancer. Compugen is headquartered in Israel, with offices in San Francisco, CA. Compugen’s shares are listed on Nasdaq and the Tel Aviv Stock Exchange under the ticker symbol CGEN.

everads therapy ltd

Everads Therapy is an early-stage life sciences company developing the next generation of retinal treatment delivery technologies. With the goal of overcoming significant challenges in current treatment methodologies for retinal and macular diseases, Everads' delivery system offers the promise of improving the efficacy and safety of existing and potential drug therapies. Established in 2017, Everads Therapy operates within the RAD Biomed incubator in Tel Aviv, Israel. Its underlying technologies have been licensed from the Sheba Medical Center at Tel Hashomer.

Identifai Genetics

By taking a simple blood test from the mother-to-be, we can read the fetal DNA! No more risky, complicated and late invasive tests like amniocentesis - we are revolutionizing the way prenatal testing is done.